ClinicalTrials.gg
RecruitingNCT07170176Updated Jan 16, 2026

Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine

An interventional study of Percutaneous Patent Foramen Ovale Closure and No Intervention in Migraine Disorders, Patent Foramen Ovale and Right-to-Left Shunt, Cardiac, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 2 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.

Planned enrollment
45th of 61
150 · median 288
Started
2026
with 9 others
No phase
21 of 80
12 open now
Primary completion
2027-05
later than 22 of 39 live
Registered
67th of 80
by date
Lead sponsor
3 of 80
First Affiliated Hospital Xi'an Jiaotong University

Among the 80 studies in Migraine Disorders with a site in China, this one is the 45th largest by planned enrollment of the 61 interventional ones that give a count, is one of 10 that started in 2026, is one of 21 with no phase, reaches primary completion later than 22 of the 39 other live ones, and was the 67th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in China, or all of them as a file.
02

Study summary

Patent Foramen Ovale (PFO) is a common congenital heart defect. Recent studies have suggested a potential association between PFO and migraines, particularly migraine with aura. It is hypothesized that PFO may allow microemboli or vasoactive substances from venous blood to bypass pulmonary metabolism and enter the arterial system directly, potentially triggering migraines. Although PFO closure has been shown to reduce the frequency and severity of migraine attacks, its long-term efficacy and underlying mechanisms require further investigation.

This study aims to explore the characteristics of glymphatic system function in PFO patients and its relationship with migraine symptoms, as well as the impact of PFO closure on glymphatic function and its role in alleviating migraine symptoms. A case-control and self-controlled before-after study design is adopted. Two groups of participants are enrolled: a case group consisting of PFO patients with significant right-to-left shunt and migraine, and a control group comprising PFO patients with significant shunt but without migraine. According to clinical guidelines and after obtaining informed consent, eligible patients in the case group undergo percutaneous PFO closure.

By comparing migraine symptoms and glymphatic function indicators both before and after the procedure between the two groups, the interventional effect of PFO closure and its potential mechanism will be investigated. The primary endpoint is the improvement in migraine symptoms, while the secondary endpoints include glymphatic function metrics. The findings of this study will provide new theoretical insights and clinical guidance for the management of PFO-related migraines.

03

Conditions studied

  • Migraine Disorders
  • Patent Foramen Ovale
  • Right-to-Left Shunt, Cardiac

Keywords

  • Patent Foramen Ovale
  • Migraine
  • Glymphatic System
  • PFO Closure
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 to 60 years.
  2. Diagnosed with patent foramen ovale (PFO) with significant right-to-left shunt.
  3. For the case group: Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders (ICHD-3).
  4. For the control group: No history of migraine.
  5. Willing and able to provide written .
  6. Education level of primary school or higher.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of PFO closure or other migraine-related surgical treatments;
  2. Patients with other severe cardiac or neurological diseases, mental disorders, or psychological conditions;
  3. Patients with to closure surgery or MRI scans (e.g., severe infection, coagulation dysfunction, cardiac pacemakers, aneurysm clips, metallic foreign bodies in the eye, non-removable metal dentures, etc.);
  4. Patients unable to complete migraine symptom assessments or imaging examinations due to other reasons.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    PFO with Migraine (Closure)

    Patients with patent foramen ovale (PFO) and migraine receive percutaneous PFO closure intervention. This group will be assessed for migraine symptoms and glymphatic function before and after the procedure.

    Device: Percutaneous Patent Foramen Ovale Closure

  • Other
    PFO without Migraine (Observation)

    Patients with patent foramen ovale (PFO) but without migraine. This group does not receive closure intervention and serves as the control group for observational comparison. They will undergo the same assessment schedule as the intervention group.

    Other: No Intervention

Interventions

  • DevicePercutaneous Patent Foramen Ovale Closure

    Percutaneous transcatheter closure of patent foramen ovale (PFO) is a minimally invasive procedure. Under local anesthesia, a closure device is delivered via a catheter through the femoral vein to the heart to seal the PFO tunnel. The procedure is performed under fluoroscopic and echocardiographic guidance. This intervention aims to eliminate right-to-left shunt, which is hypothesized to improve migraine symptoms and glymphatic function.

    Also known as: PFO Closure

  • OtherNo Intervention

    This arm does not receive the PFO closure procedure. Patients in this control group are observed under their standard care regimen without any study-specific intervention.

06

What researchers measure

Primary outcomes

  1. Monthly Migraine Days (MMD)

    The number of days with migraine headache per month, as recorded by participants in a daily headache diary. The change in MMD from baseline to 6-month follow-up will be calculated. A decrease in MMD indicates improvement.

    Time frame: For the intervention arm, this is 6 months post-procedure. For the control arm, this is 6 months post-enrollment.

Secondary outcomes

  1. Migraine Pain Intensity (VAS Score)

    The change in pain intensity of migraine attacks as measured by the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable). A negative change indicates improvement.

    Time frame: The pain intensity of migraine attacks as measured by the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable). The change in VAS score from baseline to the 6-month timepoint will be calculated. A negative change indicates

  2. DTI-ALPS Index

    The Diffusion Tensor Imaging-Alignment along the Perivascular Space (DTI-ALPS) index is a non-invasive MRI biomarker used to assess glymphatic system function. It is calculated by obtaining diffusion tensor imaging (DTI) sequences on a 3.0T MRI scanner and measuring the diffusion coefficients along the x, y, and z axes in specific regions of interest (ROIs) near the lateral ventricles. The change in the DTI-ALPS index from baseline to the 6-month timepoint will be calculated. A positive change suggests improved glymphatic activity.

    Time frame: For the intervention arm, this is 6 months post-procedure. For the control arm, this is 6 months post-enrollment.

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 16 months is close to that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2025
First posted
Sep 12, 2025
StartActual
Jan 14, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07170176
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Jan 14, 2026
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Yang Yan
Contact
yangyan3@xjtu.edu.cn
0086-029-85323865
Guoliang Li
Contact
liguoliang_med@163.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion